Matches in Wikidata for { <http://www.wikidata.org/entity/Q91029918> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- Q91029918 description "artículu científicu espublizáu n'ochobre de 2019" @default.
- Q91029918 description "scientific article published on 02 October 2019" @default.
- Q91029918 description "wetenschappelijk artikel" @default.
- Q91029918 description "наукова стаття, опублікована 2 жовтня 2019" @default.
- Q91029918 name "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 name "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 type Item @default.
- Q91029918 label "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 label "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 prefLabel "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 prefLabel "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 P1433 Q91029918-2AB9538E-658D-4B4C-85F9-7795C05D28FD @default.
- Q91029918 P1476 Q91029918-99E71920-0BC5-485C-898C-33E508EA05EE @default.
- Q91029918 P2093 Q91029918-1022FD2F-B3C6-472C-A498-FFD07C5E1329 @default.
- Q91029918 P2093 Q91029918-2230209B-EE68-4E0D-9BDE-315EE6E534FC @default.
- Q91029918 P2093 Q91029918-47CE4D9E-7E70-4B69-9CD7-47CADA02B8A5 @default.
- Q91029918 P2093 Q91029918-486A1A53-B49F-4AEE-8BED-BF65CABDA6ED @default.
- Q91029918 P2093 Q91029918-4DA8DA7E-AC81-4CC2-AAC3-D0E8A1960EE3 @default.
- Q91029918 P2093 Q91029918-4EA5828B-DDE6-4A3F-ACEC-3C5020AF2C29 @default.
- Q91029918 P2093 Q91029918-6CB60F2E-C0BF-4764-832F-61ED6D42D298 @default.
- Q91029918 P2093 Q91029918-8E50E360-279D-4580-A6B6-D88C1A514288 @default.
- Q91029918 P2093 Q91029918-B8F1937E-1A9F-4F06-AA78-B63D5AC899D5 @default.
- Q91029918 P2093 Q91029918-D01FA4FE-E67B-4F4A-9FD3-E94C87D4164C @default.
- Q91029918 P2093 Q91029918-D60EE8B3-2374-4D85-8255-D93AFF974471 @default.
- Q91029918 P2093 Q91029918-DBFC0A44-8296-4D71-AB1E-AF463AFB730B @default.
- Q91029918 P2093 Q91029918-E7FA1922-AF85-44D7-B18E-66A2FBF2A705 @default.
- Q91029918 P304 Q91029918-4F60A2E4-ADE8-4748-B658-FB155F7BC39E @default.
- Q91029918 P31 Q91029918-BD3689F3-544D-4EB9-A7FA-BD2A06DD43BB @default.
- Q91029918 P356 Q91029918-9DFFF04A-AC7C-491A-9DC4-ED45600F5EA1 @default.
- Q91029918 P478 Q91029918-71248DDA-354E-4277-8689-B6278BD24375 @default.
- Q91029918 P577 Q91029918-3158EDDB-25E6-4F8F-BCCD-FAB10AB47779 @default.
- Q91029918 P698 Q91029918-C1B7ADED-D2E7-4413-8D32-42206B60BC52 @default.
- Q91029918 P921 Q91029918-0F7BD5D0-6FB6-4B62-A470-0E12EDF513B5 @default.
- Q91029918 P921 Q91029918-92931D41-0719-4522-BFD4-DAA800AE4CB2 @default.
- Q91029918 P921 Q91029918-D83BCAC5-468C-493A-BE19-526BCD0A96DF @default.
- Q91029918 P921 Q91029918-EE0AC137-C6F3-4703-AC79-00B2D398E537 @default.
- Q91029918 P356 J.SURONC.2019.10.002 @default.
- Q91029918 P698 31670056 @default.
- Q91029918 P1433 Q14421678 @default.
- Q91029918 P1476 "Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer" @default.
- Q91029918 P2093 "Alessia D'Ignazio" @default.
- Q91029918 P2093 "Daniele Marrelli" @default.
- Q91029918 P2093 "Edoardo Francini" @default.
- Q91029918 P2093 "Franco Roviello" @default.
- Q91029918 P2093 "Guido Francini" @default.
- Q91029918 P2093 "Marco Farsi" @default.
- Q91029918 P2093 "Maria Raffaella Ambrosio" @default.
- Q91029918 P2093 "Martina Chirra" @default.
- Q91029918 P2093 "Natale Calomino" @default.
- Q91029918 P2093 "Pamela Torre" @default.
- Q91029918 P2093 "Remo Vernillo" @default.
- Q91029918 P2093 "Roberto Petrioli" @default.
- Q91029918 P2093 "Vinno Savelli" @default.
- Q91029918 P304 "2-7" @default.
- Q91029918 P31 Q13442814 @default.
- Q91029918 P356 "10.1016/J.SURONC.2019.10.002" @default.
- Q91029918 P478 "32" @default.
- Q91029918 P577 "2019-10-02T00:00:00Z" @default.
- Q91029918 P698 "31670056" @default.
- Q91029918 P921 Q238512 @default.
- Q91029918 P921 Q420207 @default.
- Q91029918 P921 Q420436 @default.
- Q91029918 P921 Q422327 @default.